Separately, N+1 Singer reduced their price target on shares of Synairgen plc from GBX 47 ($0.58) to GBX 46 ($0.57) and set a buy rating on the stock in a research report on Thursday, September 22nd.
Synairgen plc (LON:SNG) opened at 20.75 on Wednesday. The firm’s market cap is GBX 18.95 million. The firm has a 50-day moving average of GBX 33.40 and a 200 day moving average of GBX 31.24. Synairgen plc has a 52-week low of GBX 19.00 and a 52-week high of GBX 38.00.
Synairgen plc Company Profile
Synairgen plc is the United Kingdom-based holding company for Synairgen Research Limited, a respiratory drug discovery and development company. The Company is engaged in the licensing of inhaled interferon beta (IFN-b) program to AstraZeneca. Synairgen has a BioBank consisting of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or chronic obstructive pulmonary disease (COPD) (and relevant controls).
Receive News & Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related companies with MarketBeat.com's FREE daily email newsletter.